Acesion Pharma

Acesion Pharma is a Danish biotech company founded in 2011 with the slogan "Danish biotech developing novel treatments for Atrial Fibrillation." The company is focused on developing more efficacious and safer drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma's scientific foundation lies in the novel concept of treating AF by inhibiting the so-called SK channels, which are ion channels present in the heart that regulate cardiac rhythm. The company's innovative approach of blocking this ion channel with a selective drug molecule represents a promising target for developing improved treatment of AF.

Acesion Pharma has attracted significant investment, with its most recent being a €45.00M Series B investment on 26 September 2023. The funding round saw participation from prominent investors including Novo Holdings, Canaan Partners, Alpha Wave Global, and Global BioAccess Fund. The company has positioned itself at the forefront of biotechnology and pharmaceutical industries, with its headquarters based in Denmark.